Jan Onik
Family Medicine · Louisiana, MONPI 1982604930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $536 and has fallen 59.8% since, to $216 in 2025.
Across 140 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$319
- Novartis$255
- Pfizer$239
- Sunovion Pharmaceuticals Inc.$114
- Mylan Specialty L.p.$112
- Otsuka America Pharmaceutical, Inc.$106
- plus $922 from 24 others
What the payments were for
- Food & beverage$2,067100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $319 |
| Novartis | 15 | $255 |
| Pfizer | 26 | $239 |
| Sunovion Pharmaceuticals Inc. | 12 | $114 |
| Mylan Specialty L.p. | 7 | $112 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| Novo Nordisk | 7 | $101 |
| Johnson & Johnson | 4 | $98 |
| Lilly USA, LLC | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Exact Sciences | 3 | $50 |
| Alkermes, Inc. | 2 | $46 |
| GSK | 3 | $39 |
| Abbott | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $31 |
| Bayer | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Merck | 2 | $28 |
| Almatica Pharma LLC | 1 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| AstraZeneca | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$2,067 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $87,535 |
| EliquisApixaban | 95 | $65,588 |
| JardianceEmpagliflozin | 51 | $47,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $45,275 |
| VraylarCariprazine Hcl | 25 | $35,678 |
| EntrestoSacubitril/Valsartan | 48 | $31,936 |
| XareltoRivaroxaban | 27 | $26,257 |
| JanuviaSitagliptin Phosphate | 19 | $22,057 |
| MounjaroTirzepatide | 17 | $20,407 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $16,486 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $15,232 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 553 | $13,279 |
| FarxigaDapagliflozin Propanediol | 21 | $12,969 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $12,739 |
| Pramipexole ErPramipexole Di-Hcl | 14 | $11,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $101 | $87,53591 claims |
| PfizerEliquis | $239 | $65,58895 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $39 | $65,54497 claims |
| Boehringer IngelheimJardiance | $28 | $47,03651 claims |
| AbbVieVraylar, Linzess | $319 | $45,13843 claims |
| MerckJanuvia, Janumet | $28 | $37,28940 claims |
| NovartisEntresto | $255 | $31,93648 claims |
| Johnson & JohnsonXarelto | $98 | $26,25727 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $12 | $22,60134 claims |
| Lilly USA, LLCMounjaro | $79 | $20,40717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Louisiana
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.